Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Teduglutide Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Cohort A:~Inclusion Criteria:~1. Diagnosis of SBS defined as intestinal resection for congenital or acquired intestinal disease leading to dependence on PS for 90 days~2. Received teduglutide after FDA approval~3. Age ≥ 1 years and ≤ 18 years at start of teduglutide initiation~4. Weight ≥ 10 kg at start of teduglutide initiation~5. Dependent on PS at the time of teduglutide initiation~6. Subject data for primary outcome (PS energy intake in cal/kg/day) is available for medical chart abstraction at baseline (pretreatment) visit.~7. The subject or guardian signs and dates a written informed consent form and any required privacy authorization and minor provides any assent required prior to enrolment into the registry.~Exclusion Criteria:~1. Participation in the pediatric clinical trial studies of teduglutide (TED-C13-003, TED-C14-006 or SHP633-303, SHP633-304).~2. In the opinion of the investigator, the subject or guardian is at high risk for non-compliance.~Cohort B:~Inclusion Criteria:~1. Diagnosis of SBS defined as intestinal resection for congenital or acquired intestinal disease leading to dependence on PS for 90 days~2. Participated in clinical trial study (TED-C13-003, TED-C14-006) and/or extension study (SHP633-303, SHP633-304)~3. Currently receiving teduglutide~4. The subject or guardian signs and dates a written informed consent form and any required privacy authorization and minor provides any assent required prior to enrolment into the registry.~Exclusion Criteria:~1. In the opinion of the investigator, the subject or guardian is at high risk for non-compliance.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: None): Participants with SBS who started Teduglutide after FDA approval (May 2019)
- Cohort B (Type: None): Subjects who participated in any of the teduglutide pediatric clinical trial studies (TED-C13-003, TED-C14-006, SHP633-303, or SHP633-304) and subsequently started therapy with teduglutide

Based on this trial design, predict the completion outcome and termination type (if applicable).